ACE gene polymorphism and thrombotic risk in covid-19 patients: Insights from a cross-sectional study in Sudan during the second wave

The COVID-19 pandemic caused by SARS-CoV-2 has resulted in a significant global health crisis. Thrombotic events have been observed in COVID-19 patients, especially those with severe disease. This study aimed to investigate the association between ACE gene polymorphism and thrombotic risk in COVID-19 patients in Sudan. A cross-sectional study was conducted during the second wave of COVID-19 in 2021. Blood samples were collected from 161 patients, and coagulation parameters were assessed. The ACE gene polymorphism was analyzed using PCR. The results revealed that 56.5% of patients had the ACE D/D polymorphism, 35.4% had the ACE D/I polymorphism, and 8.1% had the ACE I/I polymorphism. The coagulation parameter analysis did not show significant differences between the different ACE genotypes, except for INR. This study provides insights into the genetic factors that may contribute to thrombotic risk in COVID-19 patients, specifically related to ACE gene polymorphism. Further research is warranted to better understand the underlying mechanisms and clinical implications of this association.